|
|
Stem Cell Related Patent Number US6326205
Title: | Methods for use of Mpl ligands with primitive human stem cells | Inventors: | Murray, Lesley J.; San Jose, CA, USA
Young, Judy C.; San Carlos, CA, USA | Summary: | This invention introduces novel uses of myeloproliferative leukemia receptor ligands (mpl) for the stimulation of stem cells. The invention relates to mpls such as thrombopoietin which act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and the ability to give rise to all hematopoietic cell lineages. The thrombopoietin described herein supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations, namely, of CD34+ Lin-, CD34+ Thy-1+ Lin-, and CD34+ Lin- Rh123lo, while also stimulating quiescent human stem cells to begin cycling. Therapeutic applications of such mpls include the expansion of primitive stem cells for the restoration of hematopoietic capabilities and for providing modified human stem cells in gene therapy. | Abstract: | Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34.sup.+ and CD34.sup.+ sub-populations (CD34.sup.+ Lin.sup.-, CD34.sup.+ Thy-1.sup.+ Lin.sup.-, and CD34.sup.+ Lin.sup.- Rh123.sup.lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications. | US Patent Website: | Click Here for Full Text of Patent | Title Number: | US6326205 | Application Number: | US1999000328188 | Date Filed: | 08/06/1999 | Date Published: | 04/12/2001 | Assignee: | SyStemix, Inc., Palo Alto, CA, USA |
|
|